Abstract
Hydrochlorothiazide, triamterene, and hydroxytriamterene sulfate were monitored in the plasma and urine of 24 healthy young men taking single doses of a liquid preparation containing both hydrochlorothiazide and triameterene, liquid preparations containing either of these drugs alone, and a combination tablet recently formulated with a dose ratio of hydrochlorothiazide: triamterene (1∶1,5) found to give optimal potassium-sparing effect. In contradiction to a recent publication, no interaction between the drugs affecting the bioavailability or renal clearance of either could be demonstrated. The previous report of drug-drug interaction probably arose from formulationrelated problems with bioavailability from the two capsule and two tablet products which had been studied. A well-formulated hydrochlorothiazide-triamterene combination tablet promotes plasma concentrations and urinary excretion of hydrochlorothiazide, triamterene, and hydroxytriamterene sulfate which are virtually identical to those seen after either a combination liquid dosage form or simple liquid forms containing only one of the two drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
K. B. Hansen and A. D. Bender. Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination.Clin. Pharmacol. Ther. 8:392–399 (1966).
R. E. Spiekerman, K. G. Berge, and D. L. Thurber. Potassium-sparing effects of triamterene in the treatment of hypertension.Circulation 34:524–531 (1966).
P. J. Tannenbaum, E. Rosen, T. Flanagan, and A. P. Crosley, Jr. The influence of dosage form on the activity of a diuretic agent.Clin. Pharmacol. Ther. 9:598–604 (1968).
C. D. Blume, R. L. Williams, R. A. Upton, E. T. Lin, and L. Z. Benet. Bioequivalence study of a newtablet formulation of hydrochlorothiazide.Am. J. Med. 77(Suppl. 5A):59–61 (1984).
V. P. Shah, M. A. Walker, V. K. Prasad, J. Lin, G. Knapp, and B. E. Cabana. Preliminary observations on dissolution and bioavailability of triamterene-hydrochlorothiazide combination products.Biopharm. Drug. Dispos. 5:11–19 (1984).
Metropolitan Life Insurance Bulletin. New York. Metropolitan Life Insurance Company, November–December, 1959.
E. T. Lin, Hydrochlorothiazide in plasma and urine. In P. M. Kabra and L. J. Marton (eds.),Clinical Liquid Chromatography, Vol. I, Analysis of Exogenous Compounds. CRC Press, Boca Raton, Fia, 1984, pp. 115–118.
E. T. Lin. Triamterene and its metabolite in plasma and urine. In ref. 7, pp. 123–127.
F. Sorgel, E. T. Lin, J. Hasegawa, and L. Z. Benet. Liquid Chromatographic analysis of triamterene and its major metabolite, hydroxytriamterene sulfate in blood, plasma and urine.J. Pharm. Sci. 73:831–833 (1984).
B. Beermann and M. Groschinsky-Grind. Clinical pharmacokinetics of diuretics.Clin. Pharmacokin. 5:221–245 (1980).
C. Niemeyer, G. Hasenfuss, U. Wais, H. Knauf, M. Schafer-Korting, and E. Mutschier. Pharmacokinetics of hydrochlorothiazide in relation to renal function.Eur. J. Clin. Pharmacol. 24:661–665 (1983).
Author information
Authors and Affiliations
Additional information
Data Management and Analysis were achieved largely by the NIH-sponsored PROPHET Computing System (Proc. Natl. Comp. Exp.,43: 457, 1974).
Rights and permissions
About this article
Cite this article
Upton, R.A., Williams, R.L., Lin, E.T. et al. Absence of a significant pharmacokinetic interaction between hydrochlorothiazide and triamterene when coadministered. Journal of Pharmacokinetics and Biopharmaceutics 12, 575–586 (1984). https://doi.org/10.1007/BF01059553
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059553